This inventor holds 2 USPTO granted patents and 5 published patent applications and 2 EPO patents. Top assignees: Nanocor Therapeutics, Inc., Technische Unversität Berlin. Active years: 2013-2020.
Location History:
- Luckau, DE (2013)
- Berlin, DE (2020)
Company Filing History:
Years Active: 2013-2020
Title: Henry Fechner: Innovator in RNA Interference for Heart Failure Treatment
Introduction
Henry Fechner is a notable inventor based in Munich, Germany. He has made significant contributions to the field of medical science, particularly in the treatment of heart failure through innovative approaches.
Latest Patents
Fechner holds a patent for "RNA interference for the treatment of heart failure." This invention focuses on targeted RNA interference (RNAi) to modulate defective cardiac homeostasis. It aims to decrease the expression or activity of phospholamban (PLB) using adeno-associated virus (AAV) transfection of cardiomyocytes. The patent also discloses methods for reducing ventricular arrhythmias and improving survival rates in heart failure patients. Additionally, it provides diagnostic methods for assessing susceptibility to RNAi treatment, along with pharmaceutical compositions, kits, and vectors that include RNAi sequences.
Career Highlights
Throughout his career, Fechner has worked with prominent organizations, including Nanocor Therapeutics, Inc. and Technische Universität Berlin. His work has been instrumental in advancing therapeutic strategies for heart conditions.
Collaborations
Fechner has collaborated with esteemed colleagues such as Roger J Hajjar and Wolfgang Ch Poller. Their joint efforts have contributed to the development of innovative solutions in cardiac treatment.
Conclusion
Henry Fechner's work in RNA interference represents a significant advancement in the treatment of heart failure. His innovative approaches and collaborations continue to influence the medical field positively.